Related Experiment Video
Updated: Jun 23, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Enzyme-responsive 2-dimensional nanomaterials for targeted breast cancer treatment
Lavanya N1, Vijayabharathi S1, Mohamed Nawfal Ibraheam A M1
1Department of Pharmaceutics, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, India.
Abstract:
Breast cancer remains one of the most prevalent causes of cancer deaths globally. This is because systemic toxicity, multidrug resistance and poor tumour selectivity typically make treatment less effective. Traditional drug delivery methods depend heavily on passive targeting and diffusion-controlled release. Enzyme-responsive drug delivery systems have recently been developed as a biologically precise approach that takes clinical advantage of the specialised enzymatic environment of breast tumours, such as the overproduction of matrix metalloproteinases, cathepsins and hyaluronidase. Among advanced nanocarriers, two-dimensional (2D) nanomaterials have attracted significant attention because of their high surface-to-volume ratio, ultrathin planar structure, tuneable surface chemistry, and exceptional drug-loading capacity. Graphene derivatives, black phosphorus, layered double hydroxides, transition metal dichalcogenides, and MXenes are all examples of materials that can be used to make enzyme-cleavable linkers. This paper critically discusses the enzymatic characteristics of the breast tumour microenvironment, design principles of enzyme-responsive linkers, classifications and physicochemical properties of 2D nanomaterials and their functionalization strategies. Furthermore, toxicity considerations, preclinical advancements, translational barriers, and future perspectives are analysed. Collectively, enzyme-responsive 2D nanomaterials represent a promising next-generation approach for precision breast cancer therapy, offering improved targeting efficiency, controlled drug activation, and potential theranostic integration.
Insights
Enzyme-responsive 2D nanomaterials offer a precise approach to breast cancer therapy by targeting the tumor microenvironment. These advanced materials improve drug delivery, leading to better treatment effectiveness and reduced side effects.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Breast cancer remains a leading global cause of cancer mortality.
- Conventional treatments face challenges like systemic toxicity, multidrug resistance, and poor tumor selectivity.
- Current drug delivery relies on passive targeting and diffusion, leading to suboptimal drug release and efficacy.
Purpose of the Study:
- To critically discuss enzyme-responsive 2D nanomaterials for precision breast cancer therapy.
- To analyze the enzymatic characteristics of the breast tumor microenvironment and enzyme-responsive linker design.
- To explore the properties of 2D nanomaterials and their functionalization for targeted drug delivery.
Main Methods:
- Review of enzymatic characteristics in the breast tumor microenvironment (e.g., matrix metalloproteinases, cathepsins, hyaluronidase).
- Discussion of design principles for enzyme-responsive linkers.
- Analysis of classifications, physicochemical properties, and functionalization of 2D nanomaterials (e.g., graphene derivatives, black phosphorus, MXenes).
Main Results:
- 2D nanomaterials possess high surface-to-volume ratios, ultrathin structures, and tunable chemistry for exceptional drug loading.
- Enzyme-responsive linkers enable targeted and controlled drug release by exploiting the tumor-specific enzymatic environment.
- Functionalized 2D nanomaterials demonstrate potential for improved targeting efficiency and controlled drug activation.
Conclusions:
- Enzyme-responsive 2D nanomaterials represent a promising next-generation strategy for precision breast cancer treatment.
- These nanomaterials offer enhanced targeting, controlled drug activation, and potential for theranostic integration.
- Further analysis of toxicity, preclinical advancements, and translational barriers is crucial for clinical application.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:24Modified-Release Drug Delivery Systems: Site-Targeted